Table 2 Antibody avidity over time among one-dose and three-dose participants, stratified by HPV16 serostatus at first HPV vaccination.

From: HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

Study visit

One dose (N = 774)

Three dose (N = 1158)

HPV16 seronegative

HPV16 seropositive

Seropositive/Seronegative

HPV16 seronegative

HPV16 seropositive

Seropositive/Seronegative

n

GMA (95% CI)

% change†

n

GMA (95% CI)

% change†

Ratio (95% CI)

n

GMA (95% CI)

% change†

n

GMA (95% CI)

% change†

Ratio (95% CI)

First HPV vaccination

0

N/A

N/A

27

0.78 (0.53–1.15)

N/A

N/A

0

N/A

N/A

43

0.97 (0.79–1.20)

N/A

N/A

Year 1

42

2.39 (2.13–2.68)

N/A

10

1.39 (0.88–2.18)

77.0

0.58 (0.36–0.93)

117

2.87 (2.80–2.94)

N/A

44

2.44 (2.16–2.76)

150.4

0.85 (0.75–0.96)

Year 2

47

2.62 (2.44–2.82)

9.8

9

1.81 (1.25–2.62)

30.5

0.69 (0.47–1.00)

109

2.99 (2.89–3.09)

4.0

33

2.31 (1.95–2.74)

−5.2

0.77 (0.65–0.92)

Year 3

44

2.81 (2.67–2.96)

7.2

7

1.50 (0.94–2.38)

−17.2

0.53 (0.33–0.85)

93

2.98 (2.90–3.07)

−0.2

26

2.65 (2.36–2.98)

14.5

0.89 (0.79–1.00)

Year 4

81

2.76 (2.62–2.90)

−1.9

42

1.74 (1.47–2.06)

16.3

0.63 (0.53–0.75)

152

3.02 (2.97–3.07)

1.2

39

2.47 (2.18–2.80)

−6.9

0.82 (0.72–0.93)

Year 7

119

2.76 (2.66–2.86)

0.1

43

2.00 (1.75–2.30)

15.2

0.73 (0.63–0.84)

168

3.07 (3.01–3.13)

1.8

57

2.52 (2.26–2.82)

2.2

0.82 (0.73–0.92)

Year 9

82

2.73 (2.55–2.92)

−1.1

43

1.78 (1.48–2.15)

−10.9

0.65 (0.54–0.80)

106

3.05 (2.98–3.12)

−0.8

30

2.43 (2.07–2.84)

−3.7

0.80 (0.68–0.93)

Year 11

125

2.70 (2.60–2.80)

−1.2

53

1.82 (1.55–2.13)

1.9

0.67 (0.57–0.79)

108

3.02 (2.94–3.11)

−0.8

33

2.55 (2.28–2.84)

5.0

0.84 (0.75–0.94)

Overall*

540

2.70 (2.61–2.80)

 

234

1.80 (1.55–2.08)

 

0.66 (0.57–0.77)

853

3.01 (2.96–3.05)

 

305

2.48 (2.27–2.71)

 

0.82 (0.75–0.90)

p-for-trend**

 

0.28

  

0.79

   

0.85

  

0.82

  
  1. N total number of samples, n number of samples tested per study visit, GMA Geometric Mean of the Avidity Index, CI confidence intervals, N/A not applicable.
  2. †% change was calculated based on two consecutive visits.
  3. *Overall GMAs calculated over years 1–11. P value comparing overall GMA ratios was 0.017, presented in bold.
  4. ** p-for-trend within dose group, over time in years 4–11.
Back to article page